BioSpace News Archive

Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell platform.

Bispecific Diabody Designed to Intercept B-Cell Mediated Autoimmune Diseases

Sierra Oncology, Inc. reported its financial and operational results for the second quarter ended June 30, 2019.

AVEO Oncology reported financial results for the second quarter ended June 30, 2019 and provided a business update.

BELLUS Health Inc. reported its financial and operating results for the second quarter ended June 30, 2019.

ArunA Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, announced the addition of Tony Townley to its Board of Directors.

Bicycle Therapeutics plc reported financial results for the second quarter ended June 30, 2019 and provided a clinical update.

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, reported financial results for the second quarter ended June 30, 2019 and provided an update on corporate progress.

AVROBIO, Inc. reported financial results for the second quarter ended June 30, 2019 and provided a business update.

Aldeyra Therapeutics, Inc., a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, announced quarter ended June 30, 2019 financial results and provided a corporate update.